{"id":"pf-07941944","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P2Y12 inhibitors","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Thrombolytics","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Selective serotonin reuptake inhibitors (SSRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Serotonin-norepinephrine reuptake inhibitors (SNRIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tricyclic antidepressants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Monoamine oxidase inhibitors (MAOIs)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ketoconazole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Itraconazole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rifampicin","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"Carbamazepine","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"Phenytoin","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"Phenobarbital","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"Primidone","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"Rifabutin","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"Rifapentine","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"St. John's Wort","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"CYP3A4 inducers","action":"Avoid","effect":"Decreased efficacy of PF-07941944"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased risk of bleeding"}],"contraindications":["Hypersensitivity to the active substance or to any of the excipients","Severe renal impairment","Severe hepatic impairment","Severe cardiovascular disease","Severe respiratory disease","Severe gastrointestinal disease","Pregnancy and lactation","Concomitant use with other medications that may cause QT interval prolongation"]},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07941944","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:00.481558+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:56:19.564874+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:08.138288+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:56:00.498995+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07941944","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:09.172913+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:11.381712+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"PF-07941944 is a study medicine being tested in a study to learn how different amounts are tolerated in the body of healthy adults. The study, titled \"A Multipart Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-07941944 in Healthy Adults,\" is being conducted by Pfizer.","brandName":"Pf-07941944","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Small molecule","drugClass":"Small molecule","explanation":"","oneSentence":"","technicalDetail":"PF-07941944 is a small molecule with a specified mechanism of action. However, the details are not provided."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:58.817Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07941944","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07941944","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:56:19.564950+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Liraglutide","company":"Novo Nordisk","advantage":"Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, similar to PF-07941944, used for the treatment of type 2 diabetes.","genericName":"Liraglutide"},{"name":"Semaglutide","company":"Novo Nordisk","advantage":"Semaglutide is a GLP-1 receptor agonist, similar to PF-07941944, used for the treatment of type 2 diabetes and obesity.","genericName":"Semaglutide"},{"name":"Dulaglutide","company":"Eli Lilly and Company","advantage":"Dulaglutide is a GLP-1 receptor agonist, similar to PF-07941944, used for the treatment of type 2 diabetes.","genericName":"Dulaglutide"}],"genericName":"pf-07941944","indications":{"approved":[{"name":"Pf-07941944's indications are not publicly available or I do not have access to the information"},{"name":"Please note that I am unable to verify the indications for this drug"},{"name":"If you need to know the indications for this drug, I recommend checking the FDA website or other reliable sources"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06920498","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-12-03","conditions":"Healthy Participants","enrollment":25}],"_emaApprovals":[{"date":"","name":"Pf-07941944","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:56:19.564950+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}